In The Know-November 2025

November 2025

Pdf Summary

The November 2025 edition of Ed’s List provides a curated overview of significant recent research in gynecologic oncology. Highlights include advances in therapeutic HPV vaccines, environmental risk factors, and novel treatments.<br /><br />A promising nasal HPV therapeutic vaccine using cationic nanogel delivery demonstrated induction of targeted immune T cells in mice and primates, effectively controlling cervical cancer development, supporting future clinical trials.<br /><br />Environmental exposure to perfluoroalkyl and polyfluoroalkyl substances (PFAS) showed associations with increased ovarian cancer risk, notably with MeFOSAA and PFOS, highlighting potential modifiable risk factors.<br /><br />Predictive markers for ovarian cancer treatment success were evaluated: the CA-125 Elimination Rate Constant K (KELIM) consistently predicted favorable outcomes after neoadjuvant chemotherapy, while BRCA/HRD status did not.<br /><br />In endometrial cancer, systemic immune-inflammation index (SII) was identified as an independent predictor of neoadjuvant chemotherapy efficacy. Additionally, GLP-1 receptor agonists, commonly used in metabolic disorders, exhibit molecular and preclinical promise in overcoming hormone resistance and improving treatment.<br /><br />Advanced nanotechnologies enhanced immunotherapy for metastatic ovarian cancer by delivering IL-12 via polymer-coated nanoparticles, boosting T cell responses and survival in models.<br /><br />Sentinel lymphadenectomy emerged as a new standard for early-stage cervical cancer, showing noninferior disease-free survival and fewer complications compared to full lymphadenectomy in the multicenter PHENIX trial, though questions remain about application in larger tumors and surgical techniques.<br /><br />Further insights include the role of mutant p53 in driving endocrine resistance in high-grade serous ovarian cancer, improved outcomes by combining PARP inhibitors with immunotherapy in platinum-sensitive disease, and systemic financial impacts of cancer diagnoses on patients.<br /><br />Other notable topics cover the use of urinary HPV testing, considerations for risk-reducing salpingectomy in high-risk patients, and CRISPR-based methods to enhance CAR T cell therapies.<br /><br />This comprehensive update underscores evolving diagnostics, treatment strategies, and prevention approaches shaping gynecologic oncology. Continued research and clinical translation are vital to addressing cancer burden and improving patient outcomes.

Keywords

gynecologic oncology

therapeutic HPV vaccines

cationic nanogel delivery

perfluoroalkyl substances (PFAS)

ovarian cancer risk

CA-125 Elimination Rate Constant (KELIM)

systemic immune-inflammation index (SII)

GLP-1 receptor agonists

sentinel lymphadenectomy

PARP inhibitors and immunotherapy